Cytex Therapeutics develops bio-artificial devices to treat osteoarthritis and other musculoskeletal diseases.
Cytex Therapeutics was formed to develop and commercialize the tissue regeneration technology discoveries coming out of the lab of Dr. Farshid Guilak at Duke University. The original Cytex business plan received numerous innovation awards, including seed capital for the startup phase. Since its founding, Cytex has gone on to win numerous state and federal grants, each recognizing the novelty of the research and its enormous potential contribution to the clinical management of patients with osteoarthritis. The three Cytex co-founders form the core leadership of the company as it continues to develop its novel products.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 28, 2013 | Grant | $149.99K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |